Nature Reviews Nephrology最新文献_第3页

NOX2 dampens TLR7 to protect the kidneys in SLE NOX2 可抑制 TLR7，从而保护系统性红斑狼疮患者的肾脏。

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-27 DOI: 10.1038/s41581-024-00890-6

Monica Wang

引用次数: 0

Microglial activation in CKD-associated cognitive decline 与慢性肾功能衰竭相关的认知能力下降中的小胶质细胞活化。

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-27 DOI: 10.1038/s41581-024-00891-5

Susan J. Allison

引用次数: 0

A focus on kidney ageing 关注肾脏老化

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-20 DOI: 10.1038/s41581-024-00879-1

引用次数: 0

Advances in uromodulin biology and potential clinical applications 尿调节蛋白生物学研究进展及潜在临床应用

IF 41.5 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-19 DOI: 10.1038/s41581-024-00881-7

Azuma Nanamatsu, Larissa de Araújo, Kaice A. LaFavers, Tarek M. El-Achkar

{"title":"Advances in uromodulin biology and potential clinical applications","authors":"Azuma Nanamatsu, Larissa de Araújo, Kaice A. LaFavers, Tarek M. El-Achkar","doi":"10.1038/s41581-024-00881-7","DOIUrl":"https://doi.org/10.1038/s41581-024-00881-7","url":null,"abstract":"Uromodulin (also known as Tamm–Horsfall protein) is a kidney-specific glycoprotein secreted bidirectionally into urine and into the circulation, and it is the most abundant protein in normal urine. Although the discovery of uromodulin predates modern medicine, its significance in health and disease has been rather enigmatic. Research studies have gradually revealed that uromodulin exists in multiple forms and has important roles in urinary and systemic homeostasis. Most uromodulin in urine is polymerized into highly organized filaments, whereas non-polymeric uromodulin is detected both in urine and in the circulation, and can have distinct roles. The interactions of uromodulin with the immune system, which were initially reported to be a key role of this protein, are now better understood. Moreover, the discovery that uromodulin is associated with a spectrum of kidney diseases, including acute kidney injury, chronic kidney disease and autosomal-dominant tubulointerstitial kidney disease, has further accelerated investigations into the role of this protein. These discoveries have prompted new questions and ushered in a new era in uromodulin research. Here, we delineate the latest discoveries in uromodulin biology and its emerging roles in modulating kidney and systemic diseases, and consider future directions, including its potential clinical applications.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":null,"pages":null},"PeriodicalIF":41.5,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142002784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving the quality of pharmacoepidemiological studies using the target trial emulation framework. 利用目标试验模拟框架提高药物流行病学研究的质量。

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-13 DOI: 10.1038/s41581-024-00884-4

Emilie Lambourg

引用次数: 0

From improbable to possible: pregnancy with advanced chronic kidney disease 从不可能到可能：晚期慢性肾病患者怀孕

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-07 DOI: 10.1038/s41581-024-00882-6

Alejandra Orozco-Guillén

引用次数: 0

Lymphocytes and innate immune cells in acute kidney injury and repair 急性肾损伤和修复中的淋巴细胞和先天性免疫细胞

IF 41.5 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-02 DOI: 10.1038/s41581-024-00875-5

Kyungho Lee, Hye Ryoun Jang, Hamid Rabb

{"title":"Lymphocytes and innate immune cells in acute kidney injury and repair","authors":"Kyungho Lee, Hye Ryoun Jang, Hamid Rabb","doi":"10.1038/s41581-024-00875-5","DOIUrl":"https://doi.org/10.1038/s41581-024-00875-5","url":null,"abstract":"Acute kidney injury (AKI) is a common and serious disease entity that affects native kidneys and allografts but for which no specific treatments exist. Complex intrarenal inflammatory processes driven by lymphocytes and innate immune cells have key roles in the development and progression of AKI. Many studies have focused on prevention of early injury in AKI. However, most patients with AKI present after injury is already established. Increasing research is therefore focusing on mechanisms of renal repair following AKI and prevention of progression from AKI to chronic kidney disease. CD4+ and CD8+ T cells, B cells and neutrophils are probably involved in the development and progression of AKI, whereas regulatory T cells, double-negative T cells and type 2 innate lymphoid cells have protective roles. Several immune cells, such as macrophages and natural killer T cells, can have both deleterious and protective effects, depending on their subtype and/or the stage of AKI. The immune system not only participates in injury and repair processes during AKI but also has a role in mediating AKI-induced distant organ dysfunction. Targeted manipulation of immune cells is a promising therapeutic strategy to improve AKI outcomes.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":null,"pages":null},"PeriodicalIF":41.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141877445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Making advance care planning easier for adults with kidney disease and their clinicians 让成人肾病患者及其临床医生更轻松地制定预先护理计划。

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-08-01 DOI: 10.1038/s41581-024-00871-9

Ryan D. McMahan, Rebecca L. Sudore

引用次数: 0

Drug repurposing for glomerular diseases: an underutilized resource 肾小球疾病的药物再利用：未充分利用的资源

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-07-31 DOI: 10.1038/s41581-024-00864-8

Monica Suet Ying Ng, Gursimran Kaur, Ross S. Francis, Carmel M. Hawley, David W. Johnson

{"title":"Drug repurposing for glomerular diseases: an underutilized resource","authors":"Monica Suet Ying Ng, Gursimran Kaur, Ross S. Francis, Carmel M. Hawley, David W. Johnson","doi":"10.1038/s41581-024-00864-8","DOIUrl":"10.1038/s41581-024-00864-8","url":null,"abstract":"Drug repurposing in glomerular disease can deliver opportunities for steroid-free regimens, enable personalized multi-target options for resistant or relapsing disease and enhance treatment options for understudied populations (for example, children) and in resource-limited settings. Identification of drug-repurposing candidates can be data driven, which utilizes existing data on disease pathobiology, drug features and clinical outcomes, or experimental, which involves high-throughput drug screens. Information from databases of approved drugs, clinical trials and PubMed registries suggests that at least 96 drugs on the market cover 49 targets with immunosuppressive potential that could be candidates for drug repurposing in glomerular disease. Furthermore, evidence to support drug repurposing is available for 191 immune drug target–glomerular disease pairs. Non-immunological drug repurposing includes strategies to reduce haemodynamic overload, podocyte injury and kidney fibrosis. Recommended strategies to expand drug-repurposing capacity in glomerular disease include enriching drug databases with glomeruli-specific information, enhancing the accessibility of primary clinical trial data, biomarker discovery to improve participant selection into clinical trials and improve surrogate outcomes and initiatives to reduce patent, regulatory and organizational hurdles. Drug repurposing could expand the therapeutic options available to patients with glomerular disease. Here, the authors examine different approaches to the identification of drug candidates, consider current immunosuppressive and non-immunological options and discuss strategies to maximize drug repurposing in glomerular disease.","PeriodicalId":19059,"journal":{"name":"Nature Reviews Nephrology","volume":null,"pages":null},"PeriodicalIF":28.6,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-nephrin autoantibodies: a paradigm shift in podocytopathies 抗胰岛素自身抗体：荚膜细胞病的范式转变。

IF 28.6 1区医学

Nature Reviews Nephrology Pub Date : 2024-07-30 DOI: 10.1038/s41581-024-00873-7

Zhao Cui, Ming-hui Zhao

引用次数: 0